Equities

CervoMed Inc

CRVO:NAQ

CervoMed Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.54
  • Today's Change0.01 / 0.08%
  • Shares traded65.18k
  • 1 Year change+26.16%
  • Beta1.6633
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for CervoMed Inc have a median target of 63.00, with a high estimate of 70.00 and a low estimate of 35.00. The median estimate represents a 402.39% increase from the last price of 12.54.
High458.2%70.00
Med402.4%63.00
Low179.1%35.00

Earnings history & estimates in USD

On Aug 09, 2024, CervoMed Inc reported 2nd quarter 2024 losses of -0.270 per share.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+34.48%
CervoMed Inc reported annual 2023 losses of -0.82 per share on Mar 29, 2024.
Average growth rate+72.99%
More ▼

Revenue history & estimates in USD

Diffusion Pharmaceuticals Inc. had 2nd quarter 2024 revenues of 3.29m. This bettered the 2.20m consensus of the 4 analysts covering the company. This was 115.53% above the prior year's 2nd quarter results.
Average growth rate+32.53%
Diffusion Pharmaceuticals Inc. had revenues for the full year 2023 of 7.15m. Last year the company did not report any revenues.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.